Ai‐Wu Ke
Impact in
- Cancer Research top 0.5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Hepatology top 1%
Papers in
-
- MicroRNA in disease regulation 11
- Oncology 34
- Peptidase Inhibition and Analysis 10
- Co-authors
- Jia FanGuo‐Ming ShiXiaoyong HuangZhen‐Bin DingJiabin CaiJian ZhouJia‐Cheng LuPengfei Zhang
- Journals
- Hepatology (8 papers)PLoS ONE (8 papers)Molecular Cancer (5 papers)Clinical Cancer Research (3 papers)Cell Death and Disease (3 papers)
- Partner nations
- ChinaEthiopiaUnited States
In The Last Decade
Ai‐Wu Ke
90 papers receiving 5.9k citations
Hit Papers
Peers
Comparison fields: 5 of 114
- Cancer Research 2.2k
- Hepatology 563
- Molecular Biology 3.7k
- Oncology 1.4k
- Immunology 950
Countries citing papers authored by Ai‐Wu Ke
This map shows the geographic impact of Ai‐Wu Ke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ai‐Wu Ke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ai‐Wu Ke more than expected).
Fields of papers citing papers by Ai‐Wu Ke
This network shows the impact of papers produced by Ai‐Wu Ke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ai‐Wu Ke. The network helps show where Ai‐Wu Ke may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ai‐Wu Ke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 3 | |
| 5 | 2023 | 54 | |
| 6 | 2023 | 9 | |
| 7 | 2023 | 14 | |
| 8 | Current applications and future perspective of CRISPR/Cas9 gene editing in cancer Hit paper breakdown → | 2022 | 292 |
| 9 | 2020 | 178 | |
| 10 | 2019 | 45 | |
| 11 | 2018 | 46 | |
| 12 | 2017 | 24 | |
| 13 | 2015 | 42 | |
| 14 | 2013 | 182 | |
| 15 | 2013 | 55 | |
| 16 | 2012 | 35 | |
| 17 | 2011 | 122 | |
| 18 | 2011 | 155 | |
| 19 | 2008 | 236 | |
| 20 | 2008 | 184 |
About Ai‐Wu Ke
Ai‐Wu Ke is a scholar working on Cancer Research, Oncology, Immunology, Pathology and Forensic Medicine and Hepatology, having authored 93 papers that have together received 5.9k indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers), Cancer Mechanisms and Therapy (14 papers), MicroRNA in disease regulation (11 papers), RNA modifications and cancer (11 papers), Peptidase Inhibition and Analysis (10 papers), Circular RNAs in diseases (10 papers), Ferroptosis and cancer prognosis (9 papers) and Ubiquitin and proteasome pathways (9 papers). The work is most often cited by research in Cancer Research (2.2k citations), Hepatology (563 citations), Molecular Biology (3.7k citations), Oncology (1.4k citations) and Immunology (950 citations). Ai‐Wu Ke has collaborated with scholars based in China, Ethiopia and United States. Frequent co-authors include Jia Fan, Guo‐Ming Shi, Xiaoyong Huang, Zhen‐Bin Ding, Jiabin Cai, Jian Zhou, Jia‐Cheng Lu, Pengfei Zhang, Chao Gao and Ying‐Hong Shi. Their work appears in journals such as Hepatology, PLoS ONE, Molecular Cancer, Clinical Cancer Research and Cell Death and Disease.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.